Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
Yuval Shaked(Technion – Israel Institute of Technology), Robert S. Kerbel(Sunnybrook Health Science Centre), Santosh Hariharan(Pfizer (United States)), Ofrat Beyar‐Katz(Rambam Health Care Campus), Ksenia Magidey(Rappaport Family Institute for Research in the Medical Sciences), Valeria Miller(Rappaport Family Institute for Research in the Medical Sciences), Elizabeth Pham(Sunnybrook Health Science Centre), David W. Andrews(Sunnybrook Health Science Centre), Ping Xu(Sunnybrook Health Science Centre), Shan Man(Sunnybrook Health Science Centre), Florence T.H. Wu(University of Toronto)
Cited by 58
Related Papers
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
BCL-2 family proteins: changing partners in the dance towards death
|Cell Death and Differentiation|2017|1.6k
Tumor angiogenesis: past, present and the near future
|Carcinogenesis|2000|971
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
|Journal of Neuro-Oncology|2009|514
Interstitial cells of Cajal generate a rhythmic pacemaker current
|Nature Medicine|1998|443